Sermorelin vs CJC-1295: Head-to-Head Efficacy, Dosing, and Clinical Use

HealthRX.com

No trial shows one peptide beats the other

Print or save as PDF

Key numbers

  • 7.2 cm/yrSermorelin in children with growth hormone deficiency: height velocity at 12 months, up from 4.1 cm/yr at baselineSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 30 micrograms/kgSermorelin dose in the pediatric growth hormone deficiency study, given once daily at bedtime (a trial dose, not a recommendation)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 30 to 250 micrograms/kgCJC-1295 single-injection doses used in human trials (trial protocols, not recommended doses)Source: fda.gov, as cited Nov 7, 2026

From the public record

Published papers: sermorelin and CJC-1295

PubMed indexes 25 papers that mention sermorelin in the title or abstract and 35 that mention CJC-1295. In 2025 the counts were 1 and 1.

Published papers: sermorelin and CJC-1295: the figures
MeasureValue
sermorelin: papers, all years25
CJC-1295: papers, all years35
sermorelin: papers, 2016 to 202514
CJC-1295: papers, 2016 to 202515
sermorelin: papers in 20251
CJC-1295: papers in 20251

Source: NIH National Library of Medicine, PubMed, data as of Nov 11, 2026

How this was calculated

Ran a PubMed title and abstract search for each name separately and recorded counts by publication year. No filtering by study type or quality.

Scope: PubMed records with each name in the title or abstract, all article types and species; a paper naming both counts for each

Paper counts show research attention, not which option works better. A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.

Download the data (CSV)

  • Drug A / Sermorelin, a 29-amino-acid GHRH analogue [5]
  • Drug B / CJC-1295, a 29-amino-acid GHRH analogue; the DAC form binds albumin [3][6]
  • FDA status / Sermorelin: approved as Geref, withdrawn 2009. CJC-1295: no approved product found in any country the FDA searched [4][3]
  • Half-life / CJC-1295 DAC 5.8 to 8.1 days [2]; sermorelin cleared quickly, GH raised about 3 hours after an IV dose [7]
  • Measured IGF-I effect / CJC-1295 DAC: 1.5- to 3-fold for 9 to 11 days after one dose [2]
  • Sport / Both named by WADA in S2.2.4, prohibited at all times [8]
  • Compounding lists / CJC-1295 is in no category on FDA's pharmacy or outsourcing-facility lists; sermorelin is absent from the FDA safety-risk page [9][10][11]

What are sermorelin and CJC-1295?

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH) and the shortest synthetic peptide with the full biological activity of GHRH [5]. It is not growth hormone. It prompts the pituitary to release the body's own growth hormone [5].

CJC-1295 is also a 29-amino-acid GHRH analogue, developed by ConjuChem Biotechnologies of Montreal and first described in 2005 [3]. Two forms are described: CJC-1295, and CJC-1295 DAC, the same peptide with an extra maleimidopropionic acid-lysine unit at the C-terminal end that binds it to blood albumin and makes it last much longer [3]. The preclinical paper that named the compound describes it as a tetrasubstituted form of hGRF(1-29) with that added lysine unit, detectable in rat plasma beyond 72 hours [6].

How each one acts on the pituitary

Sermorelin acts on the pituitary GHRH receptor, and its effect is brief. In a study of 30 healthy men who received intravenous or intranasal sermorelin, the peptide was rapidly eliminated after intravenous injection, while growth hormone stayed elevated for about 3 hours [7].

CJC-1295 DAC binds albumin, so its half-life is measured in days rather than minutes [2][12]. In healthy men aged 20 to 40 given one injection of 60 or 90 micrograms/kg, growth hormone pulse frequency and pulse size were unchanged a week later, while growth hormone levels between pulses rose about 7.5-fold; mean GH rose 46% and IGF-I rose 45% [12].

What the human studies actually measured

Sermorelin in children

An open-label, multicenter, one-year study treated 110 previously untreated prepubertal children with growth hormone deficiency with GHRH(1-29) 30 micrograms/kg subcutaneously at bedtime; 86 were evaluable for efficacy. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months [1].

Sermorelin in adults

The adult data in this comparison come from a small physiology study: 10 healthy men (mean age 68) took 0.5 mg and 1 mg GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, and were compared with 9 young men (mean age 26). At the 1 mg dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men [13]. It was a short physiology study, not a clinical-benefit trial [13].

CJC-1295

The FDA identified only three published human studies of CJC-1295, all of the DAC form and all in healthy volunteers: Teichman 2006, Ionescu and Frohman 2006 and Sackmann-Sala 2009. FDA identified no published CJC-1295 study in people with a disease. An unpublished phase 2 trial in HIV lipodystrophy enrolled 192 people and ended after a participant died; a causal link to CJC-1295 was neither shown nor excluded [3].

Teichman 2006 was two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61, with single doses in the first and two or three weekly or biweekly doses in the second [2]. After one injection, mean plasma GH rose 2- to 10-fold for 6 days or more and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days; the estimated half-life was 5.8 to 8.1 days; after multiple doses IGF-I stayed above baseline for up to 28 days [2]. The authors called it relatively well tolerated, particularly at 30 or 60 micrograms/kg [2]. The FDA counted 35 treated participants and 7 placebo participants in the first study [3].

No trial tested the version sold as CJC-1295 without DAC. The published human trials tested CJC-1295 DAC in healthy volunteers, and no trial showed a health benefit [3][2].

Head-to-head: what a comparison can and cannot say

The two sets of human data come from different populations, endpoints and durations: sermorelin's growth data come from children with growth hormone deficiency treated for a year [1], while CJC-1295's hormone data come from healthy adults followed for up to 49 days [2]. Hormone levels in healthy adults and height velocity in deficient children are not interchangeable measures, so the numbers cannot be lined up against each other.

What people on Reddit report

Personal accounts from a forum about the CJC blend taken with ipamorelin. Several people compare it with sermorelin, and reported results differ widely.

Similar-Working-3583 · PeptideForum

I just started this after using Sermorelin with no real effects. Night 3. I noticed my sex drive increased almost like I popped a pill or something 2 out of the 3 nights.

Reports no clear effects from sermorelin, then a noticeable change within a few nights of starting the CJC blend with ipamorelin.

Read the source discussion

Lopsided_Ad2457 · PeptideForum

I love it! After the first dose, I slept so well. I felt good and gradually had more energy and strength in the gym. It did take a few weeks for me to notice anything in the gym and with my body composition.

Reports better sleep after the first dose, with gym and body changes that took several weeks to appear.

Read the source discussion

SellEmTheSizzle · PeptideForum

Guess I need to up the dose since there have been no perceived changes so far on week 6 of nightly injections.

Reports no noticeable change after several weeks of nightly use and is considering a higher dose.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Doses used in the studies, not recommendations

Neither peptide has an FDA-approved dose today [3][4].

Sermorelin was studied at 30 micrograms/kg once daily subcutaneously at bedtime in the pediatric program [1], and at 0.5 mg or 1 mg twice daily for 14 days in the older-men study [13].

CJC-1295 was given in the human studies as single subcutaneous injections of about 30 to 250 micrograms/kg, or as two to three doses weekly or every two weeks [3][2]. Those were trial protocols, not recommended doses [3].

Side effects

CJC-1295

In the two Teichman trials, injection-site reactions occurred in about 70% of treated subjects in study 1 and in all treated subjects in study 2; headache occurred in 63% versus 14% on placebo in study 1; flushing, warmth and transient low blood pressure occurred in about 30% of treated subjects in study 1; there was transient diarrhea, and transient dizziness with low blood pressure in two subjects. Most events were more common at the higher doses of 125 or 250 micrograms/kg, and no serious adverse reactions were reported [3][2]. In the Ionescu and Frohman study no serious adverse events occurred; heart rate rose with dose, and injection sites showed transient redness and tenderness [3].

A phase 2 trial of CJC-1295 DAC in HIV lipodystrophy, with 192 people enrolled, was ended in 2006 after a participant died. The data were never published. The attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture, so a causal link is neither shown nor excluded [3].

The FDA's posted concerns are possible immunogenicity for certain routes, impurity and characterization problems, serious adverse events including increased heart rate and a systemic vasodilatory reaction, and limited clinical data [9].

Raising growth hormone and IGF-I carries the risks listed on approved growth hormone labels, such as glucose intolerance and diabetes, fluid retention and tumor growth concerns; the CJC-1295 human studies were short, small and mostly single-dose, so long-term safety is unknown [3].

Sermorelin

In the one-year pediatric study there were no adverse changes in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and sermorelin was well tolerated overall [1].

Regulatory status

Sermorelin

Two Geref applications existed: NDA 019863 (0.05 mg per ampule, for testing the pituitary's ability to secrete growth hormone, approved December 28, 1990) and NDA 020443 (0.5 mg and 1 mg vials, for idiopathic growth hormone deficiency in children with growth failure, approved September 26, 1997) [4]. The manufacturer discontinued both in 2008 and asked the FDA to withdraw the applications, which the agency did effective June 18, 2009 [4]. In March 2013 the FDA determined that Geref was not withdrawn for reasons of safety or effectiveness [4][14]. The approved uses were pediatric growth hormone deficiency and a diagnostic test only, never adults, anti-aging, weight loss or athletic performance [4]. With Geref gone, sermorelin sold in the US is compounded, and compounded drugs are not FDA-approved: the FDA does not review their safety, effectiveness or quality before they are marketed [15].

Sermorelin does not appear on the FDA's page of bulk substances that may present significant safety risks [9]. On the FDA's nominated list for outsourcing facilities it sits in category 1 (under evaluation) and is marked as a substance that is a component of FDA-approved drugs [11]. It is not in any category on the list for state-licensed pharmacies and physicians [10].

HealthRX.com offers sermorelin by prescription.

CJC-1295

CJC-1295 is not FDA-approved, and the FDA found no approved product containing any form of it in the countries it searched or authorized by the European Medicines Agency [3]. It appears on the FDA's safety-risk page in the 'nominated but withdrawn' table: it was in category 2 for significant safety risks and came off when the nominators withdrew, but the FDA's safety concerns remain posted [9]. On December 4, 2024 the FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 13 no on CJC-1295 free base, 1 yes and 12 no on the acetate form, and 0 yes and 13 no on each of the three DAC forms [16].

CJC-1295 is not in any category on the FDA's list for state-licensed pharmacies and physicians and is not on the list for outsourcing facilities; it is not a component of an FDA-approved drug and has no USP monograph [10][11]. It is not one of the six peptides in the October 2026 HHS draft enforcement-discretion policy [17]. Products sold online are mostly labeled 'research use only', including blends with ipamorelin and other growth hormone-releasing peptides, and research-use-only products are not FDA-approved drugs [3].

Sport

WADA's 2026 Prohibited List names both sermorelin and CJC-1295 in section S2.2.4 as growth hormone-releasing factors, prohibited at all times in and out of competition, and both are named in the 2027 list as well [8][18].

Is sermorelin or CJC-1295 more effective?
No trial establishes which is more effective. CJC-1295 DAC raised IGF-I 1.5- to 3-fold above baseline for 9 to 11 days after one injection in healthy volunteers, with no demonstrated clinical benefit [2][3]. Sermorelin increased height velocity in children with growth hormone deficiency [1] and raised growth hormone and IGF-I in a 14-day study of 10 older men [13].
Is CJC-1295 FDA approved?
No. The FDA found no approved product containing any form of CJC-1295 in the countries it checked and none authorized by the European Medicines Agency [3]. Sermorelin was approved as Geref for pediatric growth hormone deficiency and as a diagnostic test, but the manufacturer discontinued it and the FDA withdrew the applications in 2009 [4].
What doses were used in the studies?
Sermorelin: 30 micrograms/kg once daily at bedtime in the pediatric study [1], and 0.5 mg or 1 mg twice daily for 14 days in a study of 10 older men [13]. CJC-1295: single injections of about 30 to 250 micrograms/kg, or two to three doses weekly or every two weeks [3][2]. These are trial protocols, not recommended doses; neither peptide has an approved dose [3][4].
How long does each one stay active?
CJC-1295 DAC binds albumin and has an estimated half-life of 5.8 to 8.1 days; after one injection, IGF-I stayed above baseline for 9 to 11 days [2]. Sermorelin is cleared quickly after an intravenous dose, although growth hormone stayed raised for about 3 hours in healthy men [7].
Is CJC-1295 sold together with ipamorelin?
Online products often are. The FDA noted that CJC-1295 products sold online are mostly labeled research use only, including blends with ipamorelin and other growth hormone-releasing peptides, and that research-use-only products are not FDA-approved drugs [3].
Are sermorelin and CJC-1295 prohibited in sport?
Yes. WADA names both in section S2.2.4 of its 2026 Prohibited List as growth hormone-releasing factors, prohibited at all times in and out of competition, and both appear in the 2027 list as well [8][18].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is Sermorelin more effective than CJC-1295?

No trial establishes that sermorelin or CJC-1295 is more effective, because the human data come from different populations and endpoints. Sermorelin raised height velocity in children with growth hormone deficiency, while CJC-1295 DAC raised IGF-I 1.5- to 3-fold for 9 to 11 days in healthy adults, without a demonstrated clinical benefit.

How long will 10mg of CJC-1295 Ipamorelin last?

No dose-duration figure is established for a 10 mg product, so how long it lasts cannot be stated. CJC-1295 DAC has an estimated half-life of 5.8 to 8.1 days, and after one injection in healthy volunteers IGF-I stayed raised for 9 to 11 days. Products sold with ipamorelin are mostly labeled research use only.

Show all 19 referencesHide references
  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  3. U.S. Food and Drug Administration.
  4. Federal Register :: Request Access.
  5. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  6. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8.
  7. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
  8. World Anti-Doping Agency.
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  10. U.S. Food and Drug Administration.
  11. U.S. Food and Drug Administration.
  12. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
  13. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
  14. U.S. Food and Drug Administration.
  15. Official web page.
  16. U.S. Food and Drug Administration.
  17. Official web page.
  18. World Anti-Doping Agency.
  19. Reddit participants. How Did CJC-1295 + Ipamorelin Make You Feel? Looking for Personal Experiences! (r/PeptideForum). Accessed 2026-11-10.
Evidence overview for Sermorelin vs CJC-1295: Head-to-Head Efficacy, Dosing, and Clinical Use